All articles by GlobalData Healthcare

IDWeek 2026: early ensitrelvir PEP may benefit breakthrough and established Covid-19

Early ensitrelvir treatment could offer additional benefits for household contacts exposed to SARS-CoV-2, including reducing viral replication and symptom severity…
IDWeek 2026: ISL/LEN on track to become the first once-weekly oral HIV therapy

Daily oral antiretroviral therapy (ART) represents the current standard of care (SOC) for people with HIV (PWH). Once-weekly oral treatment…
IDWeek 2026: Abrysvo data in nursing home residents could support re-vaccination

At the IDWeek 2026 conference in Washington, DC, Dr Brigid Wilson from the VA Northeast Ohio Healthcare System and Case Western Reserve…
IDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease

At the IDWeek 2026 conference in Washington DC, Dr Paul Auwaerter, clinical director and Professor of Medicine at John Hopkins…
ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial

At the 2026 European Society for Medical Oncology (ESMO) Congress, investigators presented interim data from the Phase III MOIO study,…

ESMO26: Intismeran sets new benchmark in adjuvant melanoma

At the 2026 European Society for Medical Oncology (ESMO) Congress, full results from Merck and Moderna’s Phase III INTerpath-001 trial…
ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer

Mismatch repair-deficient (dMMR) endometrial cancer is among the most immunotherapy-sensitive solid tumours. Yet first-line treatment typically pairs immunotherapy with carboplatin…
ESMO26: Sac-TMT sets survival benchmark in recurrent endometrial cancer

Following progression on platinum-based chemotherapy and immunotherapy, patients with advanced or recurrent endometrial cancer (EC) face limited treatment options. The…
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction

Results of two Phase III trials, SANOVO and SAFFRON, with HUTCHMED and AstraZeneca’s Orpathys (savolitinib) were presented recently at the…
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open

Approximately 15% of men with very high-risk prostate cancer develop incurable distant metastases within five years of definitive treatment. Standard…

Sections